Canton Strategic Holdings (CNTN) Cash from Operations (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Cash from Operations came in at 7635188.0 in Q1 2026, down 183.94% YoY from 9095851.28 in Q1 2025, and up 26.88% on a QoQ basis from 10441616.0 in Q4 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Cash from Operations (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Cash from Operations data on file, last reported at 7635188.0 in Q1 2026.
- Quarterly Cash from Operations fell 183.94% year-over-year to 7635188.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21074503.0 (down 95.79% YoY) and the FY2025 annual result came in at 16128316.0, down 47.97% from the prior year.
- Cash from Operations advanced to 7635188.0 in Q1 2026, from 10441616.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 892676.0 in Q4 2022 to a low of 10441616.0 in Q4 2025.
- A 5-year average of 2854209.41 and a median of 2179303.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 11530.96% — and 2025, when it soared 47.57%.
- Tracing CNTN's Cash from Operations over 5 years: stood at 892676.0 in 2022, then slumped by 58.56% to 1415427.0 in 2023, then plunged by 114.19% to 3031656.0 in 2024, then slumped by 244.42% to 10441616.0 in 2025, then increased by 26.88% to 7635188.0 in 2026.
- The last three Cash from Operations figures came in at 7635188.0 (Q1 2026), 10441616.0 (Q4 2025), and 1855169.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | -2.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.24 Mn |
| Mar 31, 2026 | -7.64 Mn |
| Dec 31, 2025 | -10.43 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -2.69 Mn |
| Dec 31, 2024 | -3.03 Mn |
| Sep 30, 2024 | -2.86 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | -908,966.00 |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | -3.46 Mn |
| Dec 31, 2022 | -892,676.00 |
| Sep 30, 2022 | -1.55 Mn |
| Jun 30, 2022 | -1.39 Mn |
| Mar 31, 2022 | -2.73 Mn |
| Dec 31, 2021 | -7,675.00 |
| Sep 30, 2021 | -316,776.00 |